Sanofi has no plans for a 'major' overhaul as Dupixent's patent cliff looms
It’s been six months since Belén Garijo took over as the CEO for Sanofi, and the French drugmaker said Friday it is not planning “major” changes to its business or R&D pipeline as the early ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.